Hikma Pharmaceuticals (HIK) Ordinary GBP 0.10
20.00p
(0.99%)
- Add to watchlist
- Create an alert
- This stock can be held in a
20.00p
(0.99%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
20.00p
(0.99%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
RBC Capital ups price target on Hikma
20 May 2025 13:14
(Sharecast News) - RBC Capital Markets has upped both forecasts and its price target for blue chip generics specialist Hikma Pharmaceuticals.
-
Broker tips: Kingfisher, Accesso, Hikma
20 May 2025 07:34
(Sharecast News) - Barclays downgraded its stance on B&Q and Castorama owner Kingfisher on Tuesday to 'underweight' from 'equalweight' as it said the more than 25% year-to-date total...
-
Hikma surges as investors welcome medium-term guidance
15 May 2025 12:32
(Sharecast News) - Shares in Hikma Pharmaceuticals surged on Thursday as investors welcomed new medium-term guidance from the company.
-
London close: Burberry surges on mixed day for stocks
14 May 2025 15:02
(Sharecast News) - London stocks ended Wednesday's session narrowly mixed, as investors weighed a stream of corporate updates.
-
London close: Stocks rally on US-China tariff deal
12 May 2025 16:30
(Sharecast News) - London stocks ended higher on Monday as investors welcomed news of a temporary trade agreement between the United States and China that will see a rollback of some tariffs.
-
Hikma agrees $50m settlement for Xyrem class actions
8 May 2025 08:56
(Sharecast News) - Hikma Pharmaceuticals said on Thursday that it has entered into a preliminary $50m class settlement agreement that resolves the majority of its Xyrem (sodium oxybate) antitrust class...
-
London close: Stocks manage small gains after US jobless claims
24 April 2025 15:32
(Sharecast News) - London stocks ended marginally higher on Thursday, recovering from earlier losses as investors assessed fresh signals on the health of the US labour market.
-
Hikma Pharmaceuticals reaffirms guidance after solid start to year
24 April 2025 07:57
(Sharecast News) - Hikma Pharmaceuticals reaffirmed its full-year guidance on Thursday following a solid start to 2025, supported by stable trading across its three core divisions.
-
London close: Stocks rise as investors look to Nvidia earnings
26 February 2025 15:04
(Sharecast News) - London stocks ended higher on Wednesday, with investors maintaining a cautious yet positive stance ahead of Nvidia's earnings release in the United States later in the global day.
-
Shares in Hikma fall after results disappoint
26 February 2025 08:51
(Sharecast News) - Shares in Hikma Pharmaceuticals came under pressure in early trading on Wednesday, despite a jump in annual revenues, after core operating profits and a weaker margin disappointed.
-
London close: Stocks finish lower as Ashtead announces US move
10 December 2024 16:03
(Sharecast News) - London stocks closed in negative territory on Tuesday, weighed down by a dip in sentiment following news that Ashtead planned to shift its primary listing to the United States, adding to a...
-
RBC upgrades Hikma Pharmaceuticals to 'outperform'
10 December 2024 08:02
(Sharecast News) - Analysts at RBC Capital Markets upgraded Hikma Pharmaceuticals from 'sector perform' to 'outperform' on Tuesday as it took a look at the wider European pharmaceutical...
Company announcements Announcements
-
Director/PDMR Shareholding
9 June 2025 15:33
Hikma Pharmaceuticals
-
Director/PDMR Shareholding
5 June 2025 14:05
Hikma Pharmaceuticals
-
Director/PDMR Shareholding
3 June 2025 13:02
Hikma Pharmaceuticals
-
Fitch upgrades Hikma to ‘BBB’
29 May 2025 07:00
Hikma Pharmaceuticals
-
Director/PDMR Shareholding
20 May 2025 14:49
Hikma Pharmaceuticals
-
Medium-term Group guidance ahead of US site visit
15 May 2025 12:00
Hikma Pharmaceuticals
-
Director/PDMR Shareholding
8 May 2025 16:35
Hikma Pharmaceuticals
-
S&P upgrades Hikma to ‘BBB’
8 May 2025 10:48
Hikma Pharmaceuticals
-
Settlement agreement for Xyrem® US lawsuits
8 May 2025 08:21
Hikma Pharmaceuticals
-
Director/PDMR Shareholding
30 April 2025 13:21
Hikma Pharmaceuticals
-
Result of AGM
24 April 2025 15:55
Hikma Pharmaceuticals
-
Trading Statement
24 April 2025 07:00
Hikma Pharmaceuticals
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.